Cargando…
Vasopressin Analog [V(4)Q(5)]dDAVP Exerts Cooperative Anticancer Effects in Combination With Low-Dose 5-Fluorouracil on Aggressive Colorectal Cancer Models
BACKGROUND: Colorectal cancer (CRC) is a leading cause of cancer-associated mortality worldwide. Despite being an essential component of systemic chemotherapy for advanced CRC, 5-fluorouracil (5-FU) clinical use has severe limitations, such as high toxicity, low selectivity and drug resistance. [V(4...
Autores principales: | Sobol, Natasha T., Solerno, Luisina M., Llavona, Candela, Alonso, Daniel F., Garona, Juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681791/ https://www.ncbi.nlm.nih.gov/pubmed/38022396 http://dx.doi.org/10.14740/wjon1715 |
Ejemplares similares
-
Preclinical Efficacy of [V(4)Q(5)]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer
por: Garona, Juan, et al.
Publicado: (2019) -
The novel desmopressin analogue [V(4)Q(5)]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models
por: GARONA, JUAN, et al.
Publicado: (2015) -
Anticancer activity of repurposed hemostatic agent desmopressin on AVPR2-expressing human osteosarcoma
por: Sobol, Natasha Tatiana, et al.
Publicado: (2021) -
dDAVP Downregulates the AQP3-Mediated Glycerol Transport via V1aR in Human Colon HCT8 Cells
por: Centrone, Mariangela, et al.
Publicado: (2022) -
Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy
por: Solernó, Luisina M., et al.
Publicado: (2022)